Comparison of Clinical Effectiveness of Deslorelin Acetate and Osaterone Acetate in Dogs with Benign Prostatic Hyperplasia.

Wojciech Niżański,Joanna Pasikowska,Małgorzata Ochota,Christelle Fontaine

doi:10.3390/ani10101936

Abstract

Simple SummaryThe article compares the treatment efficacy and adverse effects of two drugs used for benign prostate hyperplasia (BPH) therapy in dogs: YpozaneTM (osaterone acetate) and SuprelorinTM (deslorelin acetate). YpozaneTM is a registered medication for this condition in dogs, whereas SuprelorinTM is registered for pharmacological castration in dogs. The clinical trial proved both drugs to be safe and effective in reducing BPH-related symptoms in dogs, and the noted adverse effects were only mild—mostly weight gain. With osaterone acetate the clinical improvement was noted sooner (from day 7 onwards) than with SuprelorinTM (from day 21 onwards), but it lasted shorter up to 24 weeks, while in the SuprelorinTM group, clinical effect remained stable until the end of the study (36 weeks). Both medications can be recommended for treatment of symptoms related to BPH in dogs, as none of the drugs had serious influence on the general health status and both provided substantial clinical improvement.This article presents the results of a randomized clinical trial, designed to compare the efficacy and therapeutic profiles of YpozaneTM (osaterone acetate—OA) or SuprelorinTM (deslorelin acetate—DA) in male dogs with clinical signs of benign prostate hyperplasia (BPH). Forty-five intact male dogs were used in the study. The Group I (negative control) included 10 healthy dogs, the Group II (positive control) included 10 dogs with confirmed BPH and no treatment, whereas Group III and IV consisted of dogs with BPH and treated either with DA (15 dogs) or OA (10 dogs). The clinical response, testosterone and estradiol levels, hematology, biochemistry, and adverse effects incidence were evaluated. Both OA and DA proved to be effective for BPH treatment in dogs, as they allowed for the clinical remission in all treated dogs. The complete alleviation of BPH symptoms was noticed sooner with the use of OA (in 80% of dogs from day 7) compared to DA (in 40% of dogs within the first 21 days). The recurrence of clinical signs related to BPH was observed from week 24 in dogs treated with OA, whereas no relapse was noticed in dogs treated with DA at the end of the 36 weeks of the observation period. In 5 dogs (33%) treated with DA, a flare-up effect (increase in the clinical signs associated with BPH) was noticed on day 7. Despite individual differences in the clinical action, both medications were effective and safe options for the treatment of symptoms related to BPH in dogs.

Highlights

Among others, the benign prostatic hyperplasia (BPH) is one of the most common age-related conditions seen in male, intact dogs
Since dogs are the only nonhuman species diagnosed with spontaneous, age-related benign prostatic hyperplasia, canine BPH cases might become a valuable model to study this problem in humans [1,2]
The obtained general blood tests results of dogs treated with osaterone acetate (OA) and deslorelin acetate (DA) confirmed that both drugs are safe, neither affect liver or kidney function, nor bone marrow activity

Summary

Introduction

The benign prostatic hyperplasia (BPH) is one of the most common age-related conditions seen in male, intact dogs. BPH is the androgen-dependent multiplication of the prostatic cell number (hyperplasia) with the subsequent increase in the cell size (hypertrophy). Since dogs (apart from some primates) are the only nonhuman species diagnosed with spontaneous, age-related benign prostatic hyperplasia, canine BPH cases might become a valuable model to study this problem in humans [1,2]. As BPH could impair fertility due to decreased libido or blood detection in the ejaculate, in stud dogs the prostatic disorders are often diagnosed earlier, before the late symptomatic stage occurs [7,8]

Methods

Results

Discussion

Conclusion